Three-dimensional structure of a Nanobody® (modeled on the VHH with pdb-code 1U0Q, Cambillau et al). The target molecule is recognized by the surface formed by three hypervariable regions located at the top of the molecule (in green, cyan and blue). Hallmarks, amino acid residues that further differentiate a camelid VHH from a human VH, can be located at different positions within the framework regions, and here are coloured red, pink and magenta.

Home News room Press releases > 2007
Press Releases

2007

20/12/2007
ABLYNX EXTENDS AGREEMENT WITH WYETH
NL

17/12/2007
ABLYNX REPORTS POSITIVE PHASE I RESULTS FOR ITS ANTI-THROMBOTIC NANOBODY®, ALX-0081
NL

10/12/2007
ABLYNX ANNOUNCES EXTENSION OF NANOBODY® DRUG DISCOVERY AND DEVELOPMENT ALLIANCE
NL

10/12/2007
ABLYNX RAISES AN ADDITIONAL €10.2 MILLION VIA THE OVER-ALLOTMENT OPTION
NL

07/12/2007
ABLYNX RETAINS IMPORTANT COMMERCIAL CLAIMS IN KEY NANOBODY®-PATENT APPEAL
NL

6/11/2007

Ablynx raises €75 million in successful IPO

nL

19/10/2007

Ablynx launches its IPO on eurolist by euronext
nL

10/10/2007

ABLYNX ANNOUNCES INTENTION TO LAUNCH AN INITIAL PUBLIC OFFERING (IPO) ON EUROLIST BY EURONEXT BRUSSELS

NL

25/09/2007

ablynx is awarded eur 1.9 million grant to explore new therapeutic uses of nanobodies®

nl

07/09/2007

Ablynx and boehringer ingelheim announce major global strategic alliance to discover, develop and commercialise novel nanobody® therapeutics

NL

06/08/2007

Ablynx strengthens management team with the appointment of dr josefin-beate holz as chief medical officer

NL     fr  

02/07/2007

Ablynx announces interim results of first nanobody® phase i study of alx-0081 (ANTI-VWF)                                  

NL     fr  

18/06/2007
Ablynx identifies novel Nanobodies® achieving SECOND milestone in Procter & Gamble collaboration 

NL     fr

08/01/2007
Ablynx and Boehringer Ingelheim sign us$265M research and licensing agreement to develop new Alzheimer's treatments

NL      fr  

 

Press releases

News archive

Email alerts

If you would like to receive updates on the company news, please
click here